New MRI Contrast Agent Detects Invasive Lung Cancer and Early Metastases
A newly developed protein-based magnetic resonance imaging contrast agent detects invasive lung cancer and metastatic lesions as small as 1 millimeter in preclinical models, according to research published in the journal Science Advances. Developed by a multi-institutional team including Georgia State University and Emory University and partially funded by the National Institutes of Health, the precision molecular imaging method targets structural proteins within the tumor microenvironment without exposing patients to ionizing radiation.
- The new protein-based MRI contrast agent, designated hProCA32.Collagen, targets type I collagen found in elevated quantities within aggressive tumors.
- Preclinical trials successfully demonstrated the detection of primary lung tumors and secondary metastases in the lungs, adrenal glands, and kidneys down to a 1-millimeter threshold.
Molecular Imaging Target and Mechanism of Action
Conventional diagnostic approaches often fail to identify lung cancer until the disease has progressed and spread to distal anatomical sites, complicating clinical management and limiting therapeutic options.
Per findings detailed in Science Advances, the hProCA32.Collagen agent targets collagen type I. This structural protein accumulates densely within the tumor microenvironment of aggressive adenocarcinomas, particularly those harboring mutations that drive rapid cellular proliferation and therapeutic resistance. By localizing to these fibrotic extracellular niches, the contrast agent alters relaxation times during magnetic resonance scanning, producing high-resolution visualization of primary lesions and micro-metastases.
Lead investigators note that the technology builds upon previous molecular imaging agents engineered to target the cancer biomarker CXCR4. Imaging studies conducted at Georgia State University’s Advanced Translational Imaging Facility confirmed that the collagen-targeted methodology maps biological features linked to tumor progression, potentially reducing reliance on invasive tissue biopsies for staging.
Multi-Institutional Collaboration and Funding Transparency
The study represents a collaborative effort across several academic institutions. Researchers from Georgia State University’s Center for Diagnostics and Therapeutics and Molecular Basis of Disease programs, including co-first authors Dongjun “Darren” Li and Oluwabukola “Sophia” Bamishaye, led the development of the contrast agent. Emory University collaborators, including co-corresponding author Wei Zhou of the Winship Cancer Institute, contributed specialized cancer models, while investigators at The University of Alabama at Birmingham provided imaging physics expertise.
Financial support for the investigation was provided in part by the National Institutes of Health. Supported in part through NIH and Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding, the company is working to move next-generation protein-based diagnosis and therapeutic agents toward clinical development.
Clinical Translation and Personalized Treatment Pathways
Translating novel oncological diagnostics from animal models to human clinical workflows requires rigorous regulatory clearance.
Beyond baseline detection, the ability to image collagen remodeling throughout primary and metastatic tumor sites holds significance for personalized medicine. Clinicians may eventually utilize the diagnostic framework to stratify high-risk patients, select targeted therapeutic regimens, and monitor longitudinal treatment responses without subjecting patients to cumulative radiation doses.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*